Results 71 to 80 of about 609,040 (315)

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma [PDF]

, 2011
PURPOSE: This analysis from an observational study of clinical practice describes the impact of febrile neutropenia (FN) on chemotherapy delivery and hospitalizations.
Rossi, F G, Lugtenburg, P.J. (Pieternella), Pieternella J. Lugtenburg, Ulrich Dührsen, Bendall, K. (Kate), Dührsen, U. (Ulrich), Silvestre, AS, Francesca G. Rossi, Jaeger, U, Jaeger, Ulrich, Gaia Rossi, F. (Francesca), Matthias Schwenkglenks, Pettengell, R, Schwenkglenks, Matthias, Rossi, FG, Salar Silvestre, A, Dührsen, U, Szabo, C. (Csilla), Johnson, Hans E., Dührsen, Ulrich, Schwenkglenks, M, Bendall, Kate, Lugtenburg, PJ, Rossi, Francesca G, Hans E. Johnson, Rossi, Francesca G., Bendall, K, Jaeger, U. (Ulrich), Szabo, Z, Johnsen, HE, Silvestre, Antonio Salar, Johnson, H.E. (Hans), Pettengell, Ruth, Lugtenburg, Pieternella J., Lugtenburg, Pieternella J, Zsolt Szabo, Ruth Pettengell, Johnsen, Hans E, Szabo, Zsolt, Silvestre, J.S. (Jean Sebastien), Schwenkglenks, M. (Matthias), Pettengell, R. (Ruth), Antonio Salar Silvestre, Ulrich Jaeger, Johnson, H E, Lugtenburg, P J, Kate Bendall   +46 more
core   +1 more source

P1206: GASTROINTESTINAL BLEEDING SIGNIFICANTLY REDUCED THE EFFICACY AND SURVIVAL OF CD19 CAR-T CELL THERAPY IN PATIENTS WITH GASTROINTESTINAL TRACT INVOLVEMENT OF REFRACTORY/RELAPSED B-CELL LYMPHOMA

HemaSphere, 2022
L. Ma, Y. Dou, R. Liu, T. Xu, F. Yang, F. Xue, P. Zheng, S. Feng, Y. Guo, H. Shi, B. Deng, X. Ke, K. Hu   +12 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

MicroRNA profiling in B cell non-Hodgkin Lymphoma : focus on the role of MYC [PDF]

, 2013
Non-Hodgkinlymfoon is een kwaadaardige vorm van kanker die uitgaat van de lymfeklieren. De ziekte wordt gekenmerkt door specifieke chromosoomafwijkingen en door afwijkende patronen van genexpressie.
Robertus, Jan Lukas,, Robertus, Jan Lukas   +1 more
core  

Gastric low-grade MALT lymphoma, high-grade MALT lymphoma and diffuse large B cell lymphoma show different frequencies of trisomy [PDF]

, 1999
Gastric MALT lymphoma is a distinct entity related to Helicobacter pylori gastritis. Some studies suggest a role for trisomy 3 in the genesis of these lymphomas, but they mainly focused on low-grade MALT lymphoma.
PhM Kluin, E Schuuring, Schuuring, E, Hoeve, M.A., Krieken, J.H.J.M. van, Hopman, A.H.N., Gisbertz, I.A., Hoeve, M A, Schuuring, E., Kluin, P., van Krieken, J H, Schouten, H C, Kluin, P M, Schouten, H.C., IAM Gisbertz, FJ Bot, Gisbertz, I A, J-W Arends, Hermans, J., Arends, J.W., HC Schouten, JHJM van Krieken, A Hopman, MA Hoeve, Hermans, J, Bot, F.J., Hopman, A, J Hermans, Bot, F J, Arends, J E, Schuuring, E; id_orcid   +30 more
core   +1 more source

PB2101: TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE

HemaSphere, 2022
E.-K. Dimitraki, C. Giatra, M. Delatola, A. Roumelioti, L. Ligdi, P. Kosmas, V. Drakopoulou, E. Souravla, I. Darmani, G. Kanelis, L. Marinos, K. Sakellariou, D. Karakasis, M. Bakiri, M. Bouzani   +14 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

The impact of molecular alterations and the immune microenvironment on the natural history of Follicular Lymphoma including transformation to Diffuse Large B cell Lymphoma [PDF]

, 2009
PhDThe natural history of follicular lymphoma is heterogeneous with numerous relapses and remissions over many years. A substantial number of patients suffer an aggressive disease course with death due to disease within 5 years of diagnosis.
Lee, Abigail Mary
core  

Fine-Needle Aspiration Cytology with Immunocytochemistry of Extranodal Manifestations of Non-Hodgkin's Lymphoma [PDF]

, 1990
Sixty-three patients with extranodal manifestations of non-Hodgkin's lymphoma were examined with fine-needle aspiration cytology and diagnosed according to the Kiel classification.
Johanssons, B, Mellstedt, H, Skoog, L, Tani, E, Biberfelds, P, Liliemark, J   +5 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source